Deep Track Capital, LP Trims Enanta Pharmaceuticals Inc (ENTA) S
Deep Track Capital, LP significantly reduced its stake in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by selling over 512,000 shares, decreasing its position by 26.20%. This move reflects a reassessment of Enanta, which is currently deemed "Significantly Overvalued" with a GF Value of $7.98 against a trading price of $13.14. The biotechnology company faces financial challenges, weak profitability, and growth metrics, prompting caution from institutional investors despite some recent price momentum.
Enanta Pharmaceuticals (Nasdaq:ENTA) - Stock Analysis
This Simply Wall St analysis provides a detailed overview of Enanta Pharmaceuticals (ENTA), a biotechnology company specializing in small molecule drugs. The report covers the company's valuation, future growth prospects (revenue forecast to grow 21.99% annually), past performance, financial health, and dividend policy, noting it is currently unprofitable but analysts expect stock price growth. It also includes market data such as share price history, volatility, and comparison against industry and market returns.
Enanta Pharmaceuticals (ENTA) Stock Faces Revenue Slip And Wider Losses
Enanta Pharmaceuticals (ENTA) experienced a 2.1% stock slip after reporting a Q3 loss with basic earnings per share at -$0.67 and a wider net loss of $19.50 million. While loss per share improved year-over-year, revenue declined from $18.31 million to $14.36 million, raising concerns about commercial cash flow and the company's ability to support its R&D pipeline amid continued losses and shareholder dilution. Investors are advised to consider the financing and execution risks associated with the company's early to mid-stage portfolio.
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot
Enanta Pharmaceuticals Inc. reported a fiscal third-quarter loss of $19.5 million, or 67 cents per share. The biotechnology company generated $14.4 million in revenue during the period. This financial snapshot was generated by Automated Insights using data from Zacks Investment Research.
Enanta Pharma misses Q3 estimates on lower royalty revenue
Enanta Pharmaceuticals missed its Q3 earnings and revenue estimates, reporting an adjusted EPS of -$0.67 against an expected -$0.50, and revenue of $14.4 million, short of the $17.4 million forecast. The shortfall was primarily due to lower royalty revenue from AbbVie’s hepatitis C virus regimen MAVYRET/MAVIRET. Despite the financial miss, Enanta highlighted progress in its RSV and immunology programs, with a Phase 2b pediatric trial underway for zelicapavir and a registrational trial expected to start in Q4 2026.
Press Release: Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2026
Enanta Pharmaceuticals announced its financial results for the fiscal third quarter ended June 30, 2026. The report details the company's financial performance during this period.
Enanta Pharma reports $19.5 million Q3 loss, advances RSV pipeline
Enanta Pharmaceuticals reported a net loss of $19.5 million for Q3 FY26, with revenue dropping 21% year-over-year to $14.4 million, missing analyst estimates. Despite financial setbacks, the company advanced its RSV pipeline, initiating the LOTUS pediatric trial and preparing for the RESOLVE adult trial. Enanta maintains a strong cash position of $211.5 million, providing financial runway into fiscal 2029.
Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Misses Expectations By $0.16 EPS
Enanta Pharmaceuticals (NASDAQ:ENTA) reported a quarterly loss of $0.67 per share, missing analyst estimates by $0.16. The biotechnology company also showed negative return on equity and net margin. Despite the earnings miss, the stock rose 0.3% during Monday trading, and institutional investors hold a significant portion of the company's shares.
Enanta Pharma misses Q3 estimates on lower royalty revenue By Investing.com
Enanta Pharmaceuticals reported third-quarter results that fell short of analyst expectations, with adjusted earnings per share of -$0.67 and revenue of $14.4 million, missing estimates of -$0.50 and $17.4 million, respectively. This underperformance was primarily due to lower royalty revenue from AbbVie’s hepatitis C virus regimen MAVYRET/MAVIRET. Despite the financial miss, Enanta highlighted progress in its RSV and immunology programs, with topline data for a Phase 2b pediatric trial expected in 2027 and a registrational Phase 2b/3 trial for high-risk adults on track for Q4 2026.
Enanta Fiscal Q3 2026 Earnings: Higher Royalty-Related Interest Expense Widens Net Loss
Enanta Pharmaceuticals reported a 21.6% decline in fiscal Q3 2026 revenue to $14.4 million due to lower MAVYRET/MAVIRET royalties. Despite narrowed operating losses from reduced clinical trial spending, the net loss widened to $19.5 million because of increased royalty-related interest expenses. The company holds $211.5 million in cash and marketable securities, expected to fund operations through fiscal 2029, and is focusing on key clinical trials and managing patent litigation risks.
Enanta Pharmaceuticals reports Q3 loss; revenue $14.4M, cash and securities $211.5M
Enanta Pharmaceuticals reported a Q3 fiscal year loss of $19.5 million on revenue of $14.4 million, with $211.5 million in cash and marketable securities. The company expects current resources to fund operations into fiscal 2029 and highlighted progress in its virology and immunology programs, including a Phase 2b pediatric trial for zelicapavir and a Phase 1 readout for EDP-978 in Q4 2026.
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) reported a Q3 loss of $0.67 per share, significantly missing the Zacks Consensus Estimate of a $0.37 loss, and its revenues of $14.36 million also fell short of expectations. Despite exceeding EPS estimates three times in the last four quarters, the company's shares have declined 12.7% year-to-date. Investors are now looking to management's commentary and future earnings outlook, with the stock currently holding a Zacks Rank #3 (Hold).
Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview
Enanta Pharmaceuticals Inc is projected to report a loss of 51 cents per share, according to a Reuters earnings preview sourced from Refinitiv. The article provides this key financial forecast ahead of the company's earnings announcement.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Enanta Pharmaceuticals (NASDAQ:ENTA) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 12-month price target of $20.29, significantly higher than its current share price of $13.22. The company, which specializes in antiviral drug discovery, saw substantial institutional ownership at 94.99% and slightly beat quarterly earnings estimates, though it remains unprofitable. Analysts anticipate a full-year loss of $1.79 per share for Enanta.
(ENTA) Risk Channels and Responsive Allocation
This article provides an AI-generated analysis of Enanta Pharmaceuticals Inc. (NASDAQ: ENTA), indicating a strong near-term sentiment potentially leading to a long-term positive bias. It highlights a significant 61.0:1 risk-reward setup targeting a 19.8% gain with minimal risk and outlines specific institutional trading strategies for different risk profiles. The analysis also includes multi-timeframe signal analysis, providing support and resistance levels for various time horizons.
ENTA|Enanta Pharmaceuticals Inc|Price:12.610|Chg%:-0.120
Enanta Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on discovering and developing small molecule drugs for virology and immunology. Their pipeline includes treatments for RSV, inflammatory diseases, SARS-CoV-2, and Hepatitis B virus, with their discovered glecaprevir being part of an HCV treatment sold by AbbVie. The article provides an overview of the company, its financial data, and key executives.
Enanta Pharmaceuticals Inc (ENTA) Valuation: PE, PB & Fair Value Analysis
This article analyzes the valuation of Enanta Pharmaceuticals Inc (ENTA), highlighting its current valuation score of 8.22 within the Pharmaceuticals industry. It details the company's P/E ratio, noting its current value of -4.91 relative to its recent highs and lows. The analysis also states that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Enanta Pharmaceuticals Inc (ENTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Enanta Pharmaceuticals Inc (ENTA), highlighting that relevant business segment and regional profit contribution data has not yet been disclosed by the company. It does, however, show a United States revenue figure of $18.61 million with a 0.00% proportion, indicating incomplete reporting at the time of publication. The page also offers current stock quotes and basic financial overview links for ENTA.
ENTA|Enanta Pharmaceuticals Inc|Price:12.730|Chg%:-0.050
Enanta Pharmaceuticals Inc (ENTA) has a high growth potential and its fundamentals are stable, though its stock market performance has been weak recently. The company is engaged in developing small molecule drugs for virology and immunology, with clinical programs focused on RSV. Analysts have rated the stock as a "Buy" with a high price target, and institutional ownership is significant.
ENTA|Enanta Pharmaceuticals Inc|Price:12.780|Chg%:-0.170
Enanta Pharmaceuticals Inc. (ENTA) closed at $12.780, down 1.31%, with a market cap of $371.40 million. Analysts rate the stock as a "Buy" with a target price of $22.833, indicating a potential upside of 76.32%. The company specializes in clinical-stage biotechnology, focusing on small molecule drugs for virology and immunology, including treatments for RSV, SARS-CoV-2, and Hepatitis B virus.
Enanta Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ENTA
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) generated $65.32 million USD in revenue last year, primarily from its Small Molecule Drugs segment. This represents a slight decrease from the previous year's $67.64 million USD. The United States was the sole geographic contributor to its revenue.
Enanta Was First to File. Pfizer Still Won. The Difference Was One Digit.
This article discusses a patent dispute where Enanta Pharmaceuticals lost to Pfizer despite filing first, due to a single digit error in their provisional patent application. The Federal Circuit affirmed that Enanta's patent for a coronavirus protease inhibitor was invalid because the provisional application did not disclose the specific compound later found in Pfizer's Paxlovid. The case highlights the critical importance of meticulous detail and accuracy in provisional patent filings, especially in competitive and fast-moving fields.
Enanta Pharmaceuticals (9EP) Q2 2024 Earnings Report - Results, Call & Slides
Enanta Pharmaceuticals reported its Q2 2024 earnings with a mixed sentiment, missing EPS estimates by CHF0.11 with an actual EPS of -CHF1.20, but beating revenue estimates with CHF13.93M. The company highlighted advancements in its RSV and immunology programs, including progress in two Phase II studies and pipeline expansion, while also noting a decline in revenue and increased net loss. Enanta projects $125 million to $145 million in R&D expenses and expects its $300 million in cash to fund operations through Q3 2027.
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA
This article provides the enterprise value to EBIT forward for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It describes the company's financial data available on TradingView, covering various financial metrics and market information. The content focuses on the specific financial ratio for the pharmaceutical company.
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – BX:9EP
The article focuses on the enterprise value to EBIT forward ratio for Enanta Pharmaceuticals, Inc. (BX:9EP) as listed on the BX Swiss exchange. It highlights the financial metric's value, change, and percentage change over a specified period. The content appears to be a stub or a section of a larger financial data page on TradingView.
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA
The article provides financial data for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), specifically focusing on its enterprise value to EBITDA forward. It indicates the stock market status as closed with no trades. The document highlights the data sources and copyright information for the financial and reference data presented.
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – DUS:9EP
The article focuses on the enterprise value to EBIT forward for Enanta Pharmaceuticals, Inc. (DUS:9EP) as listed on the Dusseldorf Stock Exchange. It provides a financial overview, though no specific values are present, and highlights the company's listing within the Health Technology and Pharmaceuticals sector. The content appears to be a financial data page from TradingView.
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – SWB:9EP
This page on TradingView provides financial information for Enanta Pharmaceuticals, Inc. (SWB:9EP), focusing on its enterprise value to forward EBITDA. The content is primarily an outline for financial data and analysis tools available on the platform, without detailed numerical figures or analytical insights here.
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – DUS:9EP
This page provides financial data, specifically the Enterprise Value to EBITDA forward, for Enanta Pharmaceuticals, Inc. (9EP) traded on the Dusseldorf Stock Exchange. It appears to be a financial data snippet from TradingView, offering a quick overview without detailed analysis or figures in this excerpt.
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – GETTEX:9EP
This page from TradingView displays financial information for Enanta Pharmaceuticals, Inc. (GETTEX:9EP), specifically focusing on its Enterprise Value to EBITDA forward metric. The content indicates that the market is currently closed, and no trades have occurred for this stock.
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – GETTEX:9EP
This page provides financial data for Enanta Pharmaceuticals, Inc. (GETTEX:9EP), specifically focusing on its enterprise value to EBIT forward. The content is hosted on TradingView, a platform offering various financial tools and market data, and includes legal disclaimers about data sources and copyrights.
Form 424B5 Enanta Pharmaceuticals Inc For: 2 July By Investing.com
This article announces the filing of Form 424B5 for Enanta Pharmaceuticals Inc. on July 2nd. It provides basic information about the filing and includes irrelevant market data and news headlines, typical of an Investing.com article.
Price to sales forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA
This page on TradingView.com focuses on the "Price to sales forward" metric for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It provides financial data and an overview of the company's valuation, indicating information about the market performance and financial health of Enanta Pharmaceuticals. The content primarily serves as a financial data point for investors and analysts.
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Small Cap Comp Growth Benchmark
Enanta Pharmaceuticals, Inc. (NasdaqGS: ENTA) has been added to the Russell Small Cap Comp Growth Benchmark, as well as the Russell 2500 Growth and Russell 2000 Growth Benchmarks. This inclusion indicates recognition of the company's growth potential within the small-cap market. The article also provides a brief overview of Enanta Pharmaceuticals, including its focus on antiviral and immunology drug discovery and development.
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Growth Benchmark
Enanta Pharmaceuticals, Inc. (NasdaqGS: ENTA) has been added to the Russell 3000E Growth Benchmark. The clinical-stage biotechnology company, focused on virology and immunology, saw its stock rise by 4.09% to 14.00 USD. This inclusion highlights the company's growth potential and ongoing developments, including its RSV clinical programs and patent dispute with Pfizer.
Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Vance Terry
This article is a statement of changes in beneficial ownership of securities for Enanta Pharmaceuticals, specifically pertaining to Director Vance Terry. It is a regulatory filing indicating transactions related to his holdings in the company.
Enanta Pharmaceuticals | SCHEDULE 13G/A: Others
This article indicates that a SCHEDULE 13G/A filing related to Enanta Pharmaceuticals (ENTA) has been submitted into the public record. The filing is categorized under "Others," suggesting a beneficial ownership report from a passive investor or another type of filer.
Enterprise value to revenue forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP
This article focuses on the enterprise value to revenue forward for Enanta Pharmaceuticals, Inc. (TRADEGATE:9EP). It lists the company's trading information on the Tradegate Exchange, indicating that the market is currently closed with no trades. The piece is primarily a financial data point presented on the TradingView platform.
Price to book forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA
This article provides the "Price to book forward" for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It is a finance-related snippet from TradingView, indicating a focus on financial metrics for the company. The content itself is minimalist, primarily showcasing the title and context within the TradingView platform.
Enanta Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ENTA)
This article provides financial actuals and estimates for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), including stock price performance, analyst forecasts, earnings, revenue, and market capitalization. It highlights the company's historical stock prices, volatility, and upcoming earnings report.
Enanta Pharmaceuticals, Inc. Actuals & Estimates (FWB:9EP)
This article provides an overview of Enanta Pharmaceuticals, Inc. (FWB:9EP) financials, analyst forecasts, and historical stock performance. It includes details on past earnings, revenue, EBITDA, and provides predictions for future financial results, noting that the company does not pay dividends. The report also lists the company's next earnings release date and key stock price milestones.
ENTA Forecast — Price Target — Prediction for 2027
This article provides a forecast for Enanta Pharmaceuticals, Inc. (ENTA) stock, including analyst price targets, historical performance, and key financial data. Eight analysts have provided 1-year price forecasts, with a maximum estimate of $32.00 and a minimum of $14.00. The company's stock has shown significant increases over the past year and the article details its market capitalization, earnings, revenue, and upcoming earnings report.
Price to earnings forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA
This article displays the "Price to earnings forward" metric for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It presents financial data for the company, accessible through TradingView, and includes general market and company information. The content primarily focuses on the stock's financial performance metric without providing detailed analysis.
Price to book forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP
This article provides financial information for Enanta Pharmaceuticals, Inc. (TRADEGATE:9EP), specifically focusing on its price to book forward value. The data is available through TradingView, which aggregates market and reference data from various providers.
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
Enanta Pharmaceuticals (ENTA) saw its shares rally 5.2% after its partner, AbbVie, received European Commission approval for Maviret to treat acute hepatitis C. Enanta receives royalties from Maviret's sales. Despite the immediate bump, the stock's future strength is uncertain as consensus EPS estimates for the upcoming quarter have remained unchanged, and the stock currently holds a Zacks Rank #3 (Hold).
EC approves label expansion for Enanta’s Maviret in acute HCV infection
The European Commission (EC) has approved Maviret (glecaprevir/pibrentasvir) for treating acute hepatitis C virus (HCV) infection in adults and children aged three years and older. This approval makes Maviret the only treatment available in the EU for both acute and chronic HCV infection. Developed in collaboration with AbbVie, shares of Enanta Pharmaceuticals (Nasdaq: ENTA) rose 5.2% following the announcement.
Form 8K Enanta Pharmaceuticals Inc For: 23 June
This article reports on an SEC Form 8K filing by Enanta Pharmaceuticals Inc for June 23. It states that the information provided is not necessarily real-time or accurate and advises readers about the high risks associated with trading financial instruments and cryptocurrencies. The article reiterates that Fusion Media is not liable for any losses incurred from trading based on its information.
Form 8K Enanta Pharmaceuticals Inc For: 23 June By Investing.com
This article reports that Enanta Pharmaceuticals Inc. filed a Form 8K on June 23. The filing is an important regulatory disclosure for public companies. The article provides the title of the filing and mentions the company's stock symbol ENTA, which had a 4.09% increase.
[8-K] ENANTA PHARMACEUTICALS INC Reports Material Event
Enanta Pharmaceuticals, Inc. (ENTA) reported via an 8-K filing that the United States Court of Appeals for the Federal Circuit affirmed a prior summary judgment ruling, invalidating Enanta's U.S. Patent No. 11,358,953. This patent was related to Pfizer Inc.'s COVID-19 antiviral, Paxlovid, thereby upholding a December 2024 decision. The ruling effectively removes the possibility of Enanta seeking damages against Pfizer based on this specific patent.
Form 8K Enanta Pharmaceuticals Inc For: 23 June By Investing.com
This article reports that Enanta Pharmaceuticals Inc. filed a Form 8K on June 23. It notes a 5.16% increase in the company's stock symbol ENTA. The filing is typical for disclosing significant events to shareholders and the SEC.
